A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations ar...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research 2023-01, Vol.29 (2), p.341-348
Main Authors:	Ligon, John A, Sundby, R Taylor, Wedekind, Mary F, Arnaldez, Fernanda I, Del Rivero, Jaydira, Wiener, Lori, Srinivasan, Ramaprasad, Spencer, Melissa, Carbonell, Amanda, Lei, Haiyan, Shern, John, Steinberg, Seth M, Figg, William D, Peer, Cody J, Zimmerman, Sara, Moraly, Josquin, Xu, Xia, Fox, Stephen, Chan, King, Barbato, Michael I, Andresson, Thorkell, Taylor, Naomi, Pacak, Karel, Killian, J Keith, Dombi, Eva, Linehan, W Marston, Miettinen, Markku, Piekarz, Richard, Helman, Lee J, Meltzer, Paul, Widemann, Brigitte, Glod, John
Format:	Article
Language:	eng
Subjects:	Adolescent Adrenal Gland Neoplasms Adult Biological Products Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Child Female Gastrointestinal Stromal Tumors - genetics Humans Kidney Neoplasms Leukocytes, Mononuclear - metabolism Male Middle Aged Paraganglioma - drug therapy Paraganglioma - genetics Pheochromocytoma Succinate Dehydrogenase - genetics Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations are often resistant to cytotoxic chemotherapy, radiotherapy, and many targeted therapies. We evaluated guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in these patient populations. Phase II study of guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle) to assess clinical activity (according to RECISTv.1.1) across three strata of patients with dSDH GIST, pheochromocytoma/paraganglioma, or HLRCC-RCC. A Simon optimal two-stage design (target response rate 30% rule out 5%) was used. Biologic correlates (methylation and metabolites) from peripheral blood mononuclear cells (PBMC), serum, and urine were analyzed. Nine patients (7 with dSDH GIST, 1 each with paraganglioma and HLRCC-RCC, 6 females and 3 males, age range 18-57 years) were enrolled. Two patients developed treatment-limiting neutropenia. No partial or complete responses were observed (range 1-17 cycles of therapy). Biologic activity assessed as global demethylation in PBMCs was observed. No clear changes in metabolite concentrations were observed. Guadecitabine was tolerated in patients with dSDH tumors with manageable toxicity. Although 4 of 9 patients had prolonged stable disease, there were no objective responses. Thus, guadecitabine did not meet the target of 30% response rate across dSDH tumors at this dose, although signs of biologic activity were noted.
ISSN:	1078-0432 1557-3265